Angiorus tablets p / o 450 + 50mg, No. 30

Therapy for symptoms of venous lymphatic insufficiency:

• - pain;

• - cramps of the lower extremities;

• - a feeling of heaviness and fullness in the legs;

• - 'tiredness' of the legs.

Therapy of manifestations of venous-lymphatic insufficiency:

• - edema of the lower extremities;

• - trophic changes in the skin and subcutaneous tissue;

• - venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Inside, during meals.

In case of venous-lymphatic insufficiency - 2 tablets per day (in one or two doses): in the morning, in the afternoon and / or in the evening.

The duration of the course of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

In acute hemorrhoids - 6 tablets per day: 3 tablets in the morning and 3 tablets in the evening for 4 days, then 4 tablets per day: 2 tablets in the morning and 2 tablets in the evening for the next 3 days.

The recommended dose for chronic hemorrhoids is 2 tablets per day.

Active ingredients: hesperidin - 50 mg, diosmin - 450 mg.

Excipients: hypromellose (oxymethylpropyl cellulose) - 6.5 mg, lactose monohydrate (milk sugar) - 42 mg, talc - 22.8 mg, magnesium stearate - 7.6 mg, sodium carboxymethyl starch (sodium starch glycolate) - 22.8 mg , microcrystalline cellulose - 158.3 mg.

The composition of the shell : opadry II yellow - 22.8 mg.

Composition of yellow opaque II: macrogol-4000 (polyethylene glycol-4000) - 4.6056 mg, titanium dioxide - 1.6188 mg, talc - 3.3744 mg, polyvinyl alcohol - 9.1200 mg, iron dye yellow oxide - 4.0812 mg.

Hypersensitivity, breastfeeding period.

Patients with rare hereditary diseases such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.

Trade name: ANGIORUS

Grouping name: Hesperidin + Diosmin

Dosage form: film-coated tablets

Composition for 1 tablet:

Active ingredients: hesperidin - 50 mg, diosmin - 450 mg.

Excipients: hypromellose (oxymethylpropyl cellulose) - 6.5 mg, lactose monohydrate (milk sugar) - 42 mg, talc - 22.8 mg, magnesium stearate - 7.6 mg, sodium carboxymethyl starch (sodium starch glycolate) - 22.8 mg , microcrystalline cellulose - 158.3 mg.

The composition of the shell : opadry II yellow - 22.8 mg.

Composition of yellow opaque II: macrogol-4000 (polyethylene glycol-4000) - 4.6056 mg, titanium dioxide - 1.6188 mg, talc - 3.3744 mg, polyvinyl alcohol - 9.1200 mg, iron dye yellow oxide - 4.0812 mg.

Description.

Biconvex tablets of oval shape, film-coated, yellow-brown color. The appearance of a tablet on a break is from light yellow to grayish yellow.

Pharmacotherapeutic group: venotonic and venoprotective agent.

Pharmacological properties

Pharmacodynamics. It has venotonic and angioprotective properties. The drug reduces the distensibility of veins and venous stasis, reduces capillary permeability and increases their resistance, improves microcirculation and lymph drainage. With systematic use, it reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of an organic and functional nature.

Pharmacokinetics. The main excretion of the drug occurs through the intestines. The kidneys, on average, excrete about 14% of the taken amount of the drug. The half-life is 11 hours.

The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine.

Indications for use

Therapy for symptoms of venous lymphatic insufficiency:

• - pain;

• - cramps of the lower extremities;

• - a feeling of heaviness and fullness in the legs;

• - 'tiredness' of the legs.

Therapy of manifestations of venous-lymphatic insufficiency:

• - edema of the lower extremities;

• - trophic changes in the skin and subcutaneous tissue;

• - venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Contraindications

Hypersensitivity, breastfeeding period.

Patients with rare hereditary diseases such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.

Application during pregnancy and during breastfeeding

Animal experiments did not reveal teratogenic effects.

Until now, there have been no reports of undesirable effects when using the drug by pregnant women.

Due to the lack of data on the excretion of the drug into breast milk, it is not recommended to take the drug during breastfeeding.

Reproductive toxicity studies have shown no effect on reproductive function in rats of either sex.

Method of administration and dosage

Inside, during meals.

In case of venous-lymphatic insufficiency - 2 tablets per day (in one or two doses): in the morning, in the afternoon and / or in the evening.

The duration of the course of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

In acute hemorrhoids - 6 tablets per day: 3 tablets in the morning and 3 tablets in the evening for 4 days, then 4 tablets per day: 2 tablets in the morning and 2 tablets in the evening for the next 3 days.

The recommended dose for chronic hemorrhoids is 2 tablets per day.

Side effect

The incidence of adverse adverse reactions is given in accordance with the WHO classification: very often (> 1/10); often (> 1/100, <1/10); infrequently (> 1/1000, <1/100); rarely (> 1/10 000, <1/1000); very rare (<1/10 000, including isolated messages); the frequency is unknown (the frequency cannot be estimated from the available data).

From the side of the central nervous system:

Rarely: dizziness, headache, general malaise.

From the digestive system:

Often: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis.

Frequency not known: abdominal pain.

Allergic reactions:

Rarely: skin rash, pruritus, urticaria.

Frequency unknown: isolated edema of the face, lips, eyelids. In exceptional cases, angioedema.

Inform the doctor about the appearance of any, including those not mentioned in this manual, undesirable reactions and sensations, as well as about changes in laboratory parameters during therapy.

Overdose

There are no data on overdose.

Interaction with other medicinal products

There are no data on interactions with other drugs.

You should inform your doctor about all medications you are taking.

special instructions

Before you start taking the drug ANGIORUS, it is recommended to consult your doctor.

In case of exacerbation of hemorrhoids, the appointment of the drug ANGIORUS does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the time specified in the section 'Dosage and Administration'. In the event that the symptoms do not disappear after the recommended course of therapy, a proctological examination should be carried out and the therapy used should be reviewed.

In the presence of disorders of venous circulation, the maximum effect of treatment is provided by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, prolonged stay on the legs, and it is also recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings to help improve blood circulation.

Contact your doctor immediately if your condition worsened or did not improve during treatment.

Influence on the ability to drive vehicles and mechanisms

Does not affect.

Release form

Film-coated tablets 50 mg + 450 mg.

10 tablets in blister strip packaging made of polyvinyl chloride film and lacquered aluminum foil.

On 20, 30, 60 tablets in polymer jars.

Each can, 2, 3, 6 blisters with instructions for use are placed in a carton box.

Storage conditions

In a dark place, at a temperature not exceeding 30 ? C. Keep out of the reach of children.

Shelf life

2 years. Do not use after the expiration date.

Vacation conditions

Available without a prescription.